Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

depatuxizumab mafodotin

An antibody-drug conjugate (ADC) consisting of depatuxizumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor (EGFR), conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of depatuxizumab mafodotin, depatuxizumab targets and binds to EGFR expressed on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ABT-414
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search